<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04676737</url>
  </required_header>
  <id_info>
    <org_study_id>TTHX-002</org_study_id>
    <nct_id>NCT04676737</nct_id>
  </id_info>
  <brief_title>TTHX1114(NM141) in Combination With DWEK/DSO</brief_title>
  <official_title>Phase 2 Study To Determine the Safety and Efficacy of TTHX1114(NM141) on the Regeneration and Migration of Corneal Endothelial Cells in Patients Undergoing DWEK/DSO</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Trefoil Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Trefoil Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open label, single-treatment, with a concurrent non-treatment control&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best Corrected Visual Acuity</measure>
    <time_frame>Day 28</time_frame>
    <description>Change from baseline</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Fuchs' Endothelial Dystrophy</condition>
  <condition>Fuchs Dystrophy</condition>
  <condition>Fuchs</condition>
  <arm_group>
    <arm_group_label>Group 1 DWEK/DSO</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Study subjects in Group 1 will undergo DWEK/ DSO and will not receive any TTHX1114</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 TTHX1114 in combination with DWEK/DSO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study subjects in Group 2 will receive TTHX1114 (5 injections) and undergo DWEK/ DSO</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3 TTHX1114 in combination with DWEK/DSO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study subjects in Group 3 will receive TTHX1114 (1 injection) and undergo DWEK/ DSO</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study subjects in Group 1a will consist of subjects in Group 1 if not recovered from DWEK/ DSO by Day 84 and will receive TTHX1114 (5 injections)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study subjects in Group 3a will consist of subjects who had participated in in Group 3 if not recovered from DWEK/ DSO by the median time observed in Group 2 and will receive TTHX1114 (4 injections)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TTHX1114(NM141)</intervention_name>
    <description>TTHX1114</description>
    <arm_group_label>Group 1a</arm_group_label>
    <arm_group_label>Group 2 TTHX1114 in combination with DWEK/DSO</arm_group_label>
    <arm_group_label>Group 3 TTHX1114 in combination with DWEK/DSO</arm_group_label>
    <arm_group_label>Group 3a</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Fuchs Endothelial Cell Dystrophy (FECD) diagnosed more than 6 months&#xD;
&#xD;
          -  Scheduled for DWEK/DSO with a planned central descemetorhexis of approx 4 to 5 mm&#xD;
&#xD;
          -  Subjects in Group 2 must have a stable Fellow Eye with adequate function&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Secondary corneal/ocular pathology in the Study Eye&#xD;
&#xD;
          -  Prior refractive surgery in the Study Eye&#xD;
&#xD;
          -  Prior exposure to TTHX1114&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Tremblay</last_name>
    <role>Study Director</role>
    <affiliation>Trefoil Therapeutics.com</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thomas M Tremblay, RN, BSN</last_name>
    <phone>+1 (415) 305-3491</phone>
    <email>ttremblay@trefoiltherapeutics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Trefoil Investigational Site 124</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Tremblay</last_name>
      <phone>415-305-3491</phone>
      <email>ttremblay@trefoiltherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>North Bay Eye Associates</name>
      <address>
        <city>Petaluma</city>
        <state>California</state>
        <zip>94954</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eduardo Chavez</last_name>
      <phone>707-769-2240</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Trefoil Investigational Site 123</name>
      <address>
        <city>Deerfield Beach</city>
        <state>Florida</state>
        <zip>33064</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Tremblay</last_name>
      <phone>415-305-3491</phone>
      <email>ttremblay@trefoiltherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Trefoil Investigational Site 119</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33907</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Tremblay</last_name>
      <phone>415-305-3491</phone>
      <email>ttremblay@trefoiltherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Price Vision Group</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marianne Price, PhD</last_name>
      <phone>317-814-2990</phone>
      <email>mprice@cornea.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tauber Eye Center</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan Hefter, CCRP</last_name>
      <phone>816-531-9100</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vance Thompson Vision - Bozeman</name>
      <address>
        <city>Bozeman</city>
        <state>Montana</state>
        <zip>59718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>406-219-0700</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vance Thompson Vision - Omaha</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68137</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>402-704-3236</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vance Thompson Vision - Fargo</name>
      <address>
        <city>W. Fargo</city>
        <state>North Dakota</state>
        <zip>58078</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>701-566-5390</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Trefoil Investigational Site 120</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Tremblay</last_name>
      <phone>415-305-3491</phone>
      <email>ttremblay@trefoiltherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vance Thompson Vision - Sioux Falls</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>605-231-9716</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 15, 2020</study_first_submitted>
  <study_first_submitted_qc>December 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 21, 2020</study_first_posted>
  <last_update_submitted>September 10, 2021</last_update_submitted>
  <last_update_submitted_qc>September 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fuchs' Endothelial Dystrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

